A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:10 - Any
Updated:3/8/2019
Start Date:March 16, 2017
End Date:August 2020
Contact:Nightstar Therapeutics
Email:researchenquiries@nightstartx.com
Phone:+44 207 611 2077

Use our guide to learn which trials are right for you!

A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)

A clinical trial of AAV8-RPGR retinal gene therapy for patients with X-linked retinitis
pigmentosa

This is a Phase 1/2/3, first-in-human, multi-centre, dose-escalation interventional study of
AAV8-RPGR in male subjects with genetically confirmed XLRP. Part I is a dose-selection study;
Part II is a dose-expansion study, comparing 2 doses, and a third untreated group to allow
for a controlled comparison of efficacy and safety.

Key inclusion Criteria:

- Male

- Part I: >= 18 years

- Part II: >= 10 years

- Documentation of a mutation in the RPGR gene

Key exclusion Criteria:

- participated in a gene therapy trial previously or a clinical trial with an
investigational drug in the past 12 weeks
We found this trial at
5
sites
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
711
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
?
mi
from 43215
Manchester,
Click here to add this to my saved trials
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials